| ipilimumab based treatment | atezolizumab based treatment | avelumab based treatment | anti-PD-(L)1 | durvalumab based treatment | durvalumab alone | nivolumab based treatment | pembrolizumab based treatment | pembrolizumab alone | pembrolizumab based treatment | sintilimab based treatment | anti-PD-(L)1 | Immune checkpoint association | nivolumab plus ipilimumab | Immune checkpoint association |
| ipilimumab plus SoC | atezolizumab alone | atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | atezolizumab plus carboplatin plus nab-paclitaxel | atezolizumab plus carboplatin plus paclitaxel | atezolizumab plus pemetrexed and platin | avelumab alone | cemiplimab | durvalumab alone | durvalumab plus osimertinib | nivolumab alone | nivolumab plus SoC | pembrolizumab alone | pembrolizumab (10mg/kg) | pembrolizumab (2mg/kg) | pembrolizumab and pemetrexed plus platin | pembrolizumab plus SoC | sintillimab plus SoC | Tislelizumab | durvalumab plus tremelimumab | nivolumab plus ipilimumab | nivolumab plus ipilimumab plus SoC | pembrolizumab plus ipilimumab |